Exhibit (a)(5)(E)

For Immediate Release
---------------------
                                                   Media:
                                                   Kathleen O'Neil
                                                   (847) 938-3895

                                                   Financial Community:
                                                   John Thomas
                                                   (847) 938-2655


            ABBOTT LABORATORIES ACQUIRES CONTROL OF VYSIS, INC.
            ---------------------------------------------------

            ABBOTT PARK, Ill., November 30, 2001-- Abbott Laboratories
(NYSE: ABT) announced today that it has acquired control of Vysis, Inc.
(Nasdaq: VYSI).  Abbott's cash tender offer to purchase all of the
outstanding common stock of Vysis expired, as scheduled, at midnight, New
York City time, on Thursday, November 29, 2001. The offer has not been
extended.

            A total of 10,192,813 shares of Vysis common stock were validly
tendered and not withdrawn prior to the expiration of the offer, including
346,500 shares subject to guaranteed delivery procedures. Abbott has
accepted all of these shares for payment. These shares represent
approximately 98.6 percent of Vysis's outstanding shares.

            As the final step of the acquisition process, Abbott intends to
consummate a merger in which remaining Vysis shareholders will receive the
same $30.50 cash price per share as paid in the tender offer.

            Abbott Laboratories is a global, diversified health care
company devoted to the discovery, development, manufacture and marketing of
pharmaceuticals, nutritionals, and medical products, including devices and
diagnostics. The company employs approximately 70,000 people and markets
its products in more than 130 countries. In 2000, the company's sales and
net earnings were $13.7 billion and $2.8 billion, respectively, with
diluted earnings per share of $1.78.

            Abbott's news releases and other information are available on
the company's Web site at www.abbott.com.

            Vysis is a genomic disease management company that develops,
commercializes and markets DNA-based clinical products providing
information critical to the evaluation and management of cancer, prenatal
disorders and other genetic diseases. The company has direct sales
operations in the United States and Europe; a marketing partnership in
Japan with Fujisawa Pharmaceutical Co.; and a worldwide distribution
network. Vysis' news releases and other information are available on the
company's Web site at www.vysis.com.